Borelioza

1. Steere A.C.: Lyme disease. N. Engl. J. Med. 1989, 321, 9, 586-596. 2. Nadelmann R.B., Wormser G.P.: Lyme borreliosis. Lancet 1998, 352, 9127, 557-565. 3. Flisiak R.: Borelioza. W: Choroby przenoszone przez kleszcze. Pod red. Prokopowicz D. Wyd. Fundacji Buchnera 1995, 119-143. 4. Siński E., Rijpkema S.G.: Występowanie zakażeń Borrelia burgdorferi s.l. u kleszczy Ixodes ricinus tichs w miejskim i podmiejskim biotopie leśnym. Przegl. Epidemiol. 1997, 51, 4, 431-435. 5. Farher H., i wsp.: Longterm survey (7 years) in a population risk for Lyme borreliosis: what happens to the seropositive individuals? Eur. J. Epidemiol. 1998, 14, 2, 117-123. 6. Pancewicz S.A., i wsp.: Obecność przeciwciał przeciwko Borrelia burgdorferi wśród mieszkańców północno-wschodniej Polski Przegl. Epidemiol., 1996, 50, 4, 375-381. 7. Magdzik W., i wsp.: Choroby zakaźne i pasożytnicze – epidemiologia i profilaktyka. α-Medica Press 2004, 38-41. 8. Halperin J.J.: Nervous system Lyme disease. J. Neurol. Sci. 1998, 153, 2, 182-191. 9. Kan I., et al.: Pseudotumor cerebri in Lyme disease: a case report and literature review. Pediatr. Neurol. 1998, 18, 5, 439-441. 10. Berglund J., i wsp.: An epidemiologic study of Lyme disease in southern Sweden. N. Engl. J. Med. 1995, 333, 1319-1324. 11. Shapiro E.D., Gerber M.A.: Lyme disease in children. Semin. Neurol. 1997, 17, 1, 39-44. 12. Christen H-J., i wsp.: Epidemiology and clinical manifestations of Lyme borreliosis in childhood: a prospective multicentre study with special regards to neuroborreliosis. Acta Paediatr., 1993, 82 (suppl. 386), 1-76. 13. Dressler F.: New aspects in the diagnosis and treatment of Lyme arthritis. Rev. Rhum. (Engl. Ed.) 1997, 64 (10 suppl.), 207S-208S. 14. Sigal S.H.: Early disseminated Lyme disease: cardiac manifestations. Am. J. Med., 1995, 98 (suppl.4a), 25S-29S. 15. Zaidman G.W.: The ocular manifestations of Lyme Disease. Int. Ophthalmol. Clin., 1997, 37, 2, 13-28. 16. Horovitz H.W., i wsp.: Liver function in early Lyme disease. Hepatology 1996, 23, 6, 1412-1417. 17. Oksi J., i wsp.: Subacute multiple-site ostemyelitis caused by Borrelia burgdorferi. Clin. Infect. Dis., 1994, 19, 891-896. 18. Schwartzberg M., et al.: Lyme borreliosis presenting as a polymyalgia rheumatica- like syndrome. Br. J. Rheum., 1995, 34, 392-398. 19. Silver H.M.: Lyme disease during pregnancy Infect. Dis. Clin. N. Am., 1997, 11, 1, 93-97. 20. Aguero-Rosenfeld M.E., et al.: Diagnosis of Lyme borreliosis. Clin. Microbiol. Rev., 2005, 18(3): 484-509. 21. Bunikis J., Barbour AG.: Laboratory testing for suspected Lyme disease. Med. Clin. North Am., 2002, 86, 311-340. 22. Heikkila T., et al.: New antigens for serologic diagnosis of neuroborreliosis in children. Pediatr. Infect. Dis. J. 2005, 24, 709-712. 23. Wharton M., et al.: Case definitions for public health surveillance. MMWR Recomm. Rep., 1990, 39(RR-13), 1-43. 24. Wormser G.P., et al.: Practice guidelines for the treatment of Lyme disease. Clin. Infect. Dis., 2000, 31(suppl.1), S1-S14. 25. Taylor R.S., Simpson I.N.: Review of treatment options for lyme borreliosis. J. Chemother. 2005, 17, suppl. 2, 3-16. 26. Krupp L.B., et al.: Study and treatment of Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003, 60, (12), 1923-1930. 27. Aguero-Rosenfeld M.E., et al.: Evolution of serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J. Clin. Microbiol., 1996, 34, 1, 1-9. 28. Kalish R.A., et al.: Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin. Infect. Dis., 2001, 33(6), 780-785. 29. Peltomaa M., et al.: Persistence of the antibody response to the VisE sixth invariant region (IR6) peptide of Borrelia burgdorferi after successful antibiotic treatment of Lyme disease. J. Infect. Dis., 2003, 187, (8), 1178-86. 30. Hayes E.B., Piesman J.: How can we prevent Lyme disease? N. Engl. J. Med., 2003, 348, 2424-2430.